181
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Muscimol delays lipopolysaccharide-induced preterm delivery in mice: role of GABAA receptors and nitric oxide

, , , , , , & show all
Pages 36-43 | Received 24 Mar 2012, Accepted 07 Aug 2012, Published online: 15 Sep 2012
 

Abstract

Objectives: Immunologic processes are involved in preterm delivery (PTD). Considering the anti-inflammatory properties of muscimol (GABAA agonist), the effect of this drug was evaluated in lipopolysaccharide-induced PTD in mice. Methods: PTD was induced by two intraperitoneal injections of lipopolysaccharide (35 µg/kg; n = 11), on gestational day 15 (d15). Muscimol was administered twice on d14 and twice on d15 (1 h prior to each lipopolysaccharide injection; 0.05, 0.1, 0.2 mg/kg; intraperitoneally; n = 8–12). To assess the involved mechanisms, either bicuculline (GABAA antagonist; 0.1 and 1 µg/kg; intraperitoneally; n = 6–7) or Nω-nitro-l-arginine methyl ester (l-NAME; non-selective inhibitor of nitric oxide (NO) synthase enzymes; 2 mg/kg; intraperitoneally; n = 6) were administered 1 h before each muscimol administration on d14 and the first dose of muscimol on d15. Maternal plasma and amniotic fluid nitrite + nitrate levels, placental histopathologies and uterine contractions were assessed. Results: Muscimol (0.1 mg/kg) significantly decreased lipopolysaccharide-induced PTD rates from 100 to 50% and delayed delivery time from d16 to d18. Muscimol moderately increased maternal plasma and amniotic fluid nitrite + nitrate concentrations and decreased lipopolysaccharide-induced placental inflammation and surge in nitrite + nitrate levels. Contrary to bicuculline, l-NAME reversed the beneficial effects of muscimol. Muscimol did not affect myometrial contractions. Conclusions: Muscimol inhibits lipopolysaccharide-induced PTD through modulating NO release.

Acknowledgements

We wish to thank the reviewer of this article for his/her constructive comments.

Declaration of Interest: This study was supported by grant 9794 from the vice-chancellor for research of Tehran University of Medical Sciences.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.